<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01994031</url>
  </required_header>
  <id_info>
    <org_study_id>NJLYSK-LPS-2013-01</org_study_id>
    <nct_id>NCT01994031</nct_id>
  </id_info>
  <brief_title>Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments</brief_title>
  <official_title>Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Luye Sike Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Luye Sike Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose (MTD)of paclitaxel
      liposome injection and to compare the pharmacokinetic characters between paclitaxel liposome
      injection and paclitaxel injection and to value the effectiveness for cancer treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose(MTD)of paclitaxel liposome injection</measure>
    <time_frame>completion of cycle 1(28 days)</time_frame>
    <description>Graded and described using National Cancer Institute(NCI)Common Terminology Criteria for adverse events (CTCAE 4.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>dose-limiting toxicities(DLTs) of paclitaxel liposome injection</measure>
    <time_frame>completion of cycle 1 (28 days)</time_frame>
    <description>Graded and described using National Cancer Institute(NCI)Common Terminology Criteria for adverse events (CTCAE 4.0)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic characters of paclitaxel liposome injection compared with paclitaxel injection</measure>
    <time_frame>0,during infusion 1.5h, 3h, after infusion 15min, 30min, 1h,2h,4h,8h,12h,24h,36h,48h,72 h</time_frame>
    <description>Peak Plasma Concentration(Cmax), peak time (Tmax), Half life(T1/2), Area under the plasma concentration versus time curve(AUC0-t), Clearance (CL/F), Apparent volume of distribution(Vd/F), Mean Residence Time (MRT),</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose level A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel liposome injection 135mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel liposome injection 175mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel liposome injection 210mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel liposome injection 250mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel liposome injection 300mg/m2 on day 1, First cycle 28 days and subsequent cycles each 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel injection 175mg/m2 on day 1, each 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel liposome injection</intervention_name>
    <arm_group_label>Dose level A</arm_group_label>
    <arm_group_label>Dose level B</arm_group_label>
    <arm_group_label>Dose level C</arm_group_label>
    <arm_group_label>Dose level D</arm_group_label>
    <arm_group_label>Dose level E</arm_group_label>
    <other_name>LIPUSU®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel injection</intervention_name>
    <arm_group_label>Comparator</arm_group_label>
    <other_name>Taxol®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient willing to sign an Investigational Review Board(IRB) approved written informed
             consent document

          -  patient age: 18 years -75years

          -  patient must have histologically confirmed solid tumor

          -  patient must have uncurable and unresectable solid tumor of advanced stages

          -  patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  patient must have a life expectancy at least 12 weeks

          -  patient must have at least one lesion measurable according to Response Evaluation
             Criteria in Solid Tumors (RECIST) 1.0

          -  patient must have progress or recurrence after at least one chemotherapy regimen for
             advanced stage

          -  patient must have adequate marrow,hepatic and renal function: defined as ANC≥2.0 ×
             109/L，PLT ≥10 ×109/dL, Hb ≥ 9g/dL;GOT/GPT≤2.5×ULN；Toltle bilirubin ≤1.5×ULN; Serum
             creatinine ≤1.5×ULN or Creatinine clearance≥40ml/min(according to Cockcroft-Gault；

          -  patient must have the left ventricular ejection fraction (LVEF)≥50% confirmed by
             ultrasonic heart scanning

          -  women must have the negative pregnancy test; women and men must agree to use adequate
             contraception

        Exclusion Criteria:

          -  patient must non have received any other antitumor therapy, including chemotherapy,
             radiotherapy, hormonal therapy, biological therapy, immunotherapy and any other
             investigational agent within 4 weeks prior to starting study

          -  patient must non have any pre-existing toxity from prior antitumor therapy (any≥ grade
             2, any≥1 peripheral neuropathy, excluding alopecia)

          -  patient must non have uncontrolled cerebral metastases

          -  patient must non have any uncontrolled heart illness including, but not limited to,
             ongoing symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, arterial hypertension (≥180/110), heart failure and myocardial infarction
             within 6 months prior to starting study

          -  Patient must not have a history of a malignancy tumor except for the following:
             adequately treated localized basal cell or squamous cell carcinoma of the skin,
             carcinoma in situ of the cervix for at least 5 years

          -  patient must non have any serious illness including, but not limited to hepatic,
             renal, respiratory and uncontrolled diabetes mellitus

          -  patient must non have psychiatric illness/social situations that would limit
             compliance with study requirements.

          -  patient must non have active or uncontrolled infection including, but not limited to
             tuberculosis,HIV,HBV, HCV

          -  Patient must non be receiving any other antitumor agent

          -  patient must non be pregnant and/or breastfeeding

          -  patient must non be receiving protease inhibitors,inhibitors of CYP3A4,antifungal
             agents and inducing agent of CYP3A4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jifang Gong, MD</last_name>
    <phone>008601088196561</phone>
    <email>goodjf@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Jiang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jifang Gong</last_name>
      <phone>00861088196561</phone>
      <email>goodjf@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.52 Fucheng Road, Haidian District,Beijing,</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jifang Gong</last_name>
      <phone>008601088196561</phone>
      <email>goodjf@163.com</email>
    </contact>
    <investigator>
      <last_name>Lin Shen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>November 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>August 26, 2014</last_update_submitted>
  <last_update_submitted_qc>August 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>paclitaxel liposome injection</keyword>
  <keyword>paclitaxel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

